SCHEMBL14585407

SCHEMBL14585407

CN(C)CCCNc1nc(CN2CCN(C(=O)C3Cc4ccccc4C3)CC2)nc2ccccc12

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 1/20 0.49
▸ EHMT2 Q96KQ7 1/20 0.49
▸ TERT O14746 4/20 0.48
▸ ALDH1A1 P00352 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ RAD52 P43351 4/20 0.43
▸ POLB P06746 3/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ TOP2A P11388 2/20 0.42
▸ FLT3 P36888 6/20 0.42
▸ KMT2A Q03164 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ SLC2A1 P11166 1/20 0.41
▸ APOBEC3A P31941 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ APOBEC3G Q9HC16 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14585421 0.94 KDM1A (0.47) KDM1AEHMT2TERTALDH1A1MAPK1
SCHEMBL14585382 0.92 KDM1A (0.53) KDM1AEHMT2TERTALDH1A1MAPK1
SCHEMBL14585392 0.90 KDM1A (0.51) KDM1AEHMT2TERTALDH1A1MAPK1
SCHEMBL14585380 0.90 KDM1A (0.51) KDM1AEHMT2TERTALDH1A1MAPK1
SCHEMBL14585436 0.89 KDM1A (0.50) KDM1AEHMT2TERTALDH1A1MAPK1
SCHEMBL14585385 0.87 KDM1A (0.48) KDM1AEHMT2TERTALDH1A1MAPK1
SCHEMBL14585376 0.86 KDM1A (0.52) KDM1AEHMT2TERTALDH1A1MAPK1
SCHEMBL14628129 0.86 KDM1A (0.51) KDM1AEHMT2TERTALDH1A1MAPK1
SCHEMBL14585377 0.85 ALDH1A1 (0.52) KDM1AEHMT2TERTALDH1A1MAPK1
SCHEMBL14585364 0.85 KDM1A (0.50) KDM1AEHMT2TERTALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032502-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-02-08 — — US disclosed
US-20070032502-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-02-08 — — US disclosed
WO-2007011623-A1 QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT SCHERING CORPORATION (US) 2007-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032502-A1 Quinazoline derivatives useful in cancer treatment TP53, ACIN1, TP53BP1 KDM1A 1966/4885EHMT2 3519/4885TERT 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback